Pilot study with pegylated liposomal doxorubicin for advanced or unresectable hepatocellular carcinoma
2001
Pilot study on pegylated liposomal doxorubicin for liver cancer
Sample size: 17
publication
Evidence: low
Author Information
Author(s): Schmidinger M, Wenzel C, Locker G J, Muehlbacher F, Steininger R, Gnant M, Crevenna R, Budinsky A C
Primary Institution: University of Vienna
Hypothesis
Can pegylated liposomal doxorubicin provide clinical benefits for patients with advanced hepatocellular carcinoma?
Conclusion
The study found that pegylated liposomal doxorubicin achieved a clinical benefit response in 50% of patients with advanced hepatocellular carcinoma.
Supporting Evidence
- 50% of patients achieved a clinical benefit response.
- Complete remission was observed in 7% of patients.
- Minor remission was also seen in 7% of patients.
- 36% of patients had stable disease.
- Toxicities from the treatment were moderate.
Takeaway
Doctors tested a new cancer drug on 17 patients, and half of them got better in some way.
Methodology
Seventeen patients received 40 mg/m2 of pegylated liposomal doxorubicin intravenously every 4 weeks.
Limitations
The study is a pilot study with a small sample size.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website